{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidtyb4xnxy26fe4wd6xo3beqguozsi6hy5r7zrdo6fuovxcapxzwm",
    "uri": "at://did:plc:k7h5fn3kdhjpj37pc6yhno2o/app.bsky.feed.post/3mikizljwgbb2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreicicgsn3jt7ukqt52enrxm4gsmdmt4cjoewptxsb4fcu5msg356ua"
    },
    "mimeType": "image/jpeg",
    "size": 135031
  },
  "path": "/article/how-eli-lillys-new-glp-1-pill-stacks-up-against-wegovy-and-other-weight-loss/",
  "publishedAt": "2026-04-02T18:00:00.000Z",
  "site": "https://www.scientificamerican.com",
  "textContent": "This week the U.S. Food and Drug Administration approved a second GLP-1 pill for weight loss. The drug, called Foundayo, resulted in an average of 27 pounds lost in 72 weeks",
  "title": "How Eli Lilly’s new GLP‑1 pill stacks up against Wegovy and other weight‑loss drugs"
}